Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Japanese Prescription Sleeping Pill Daily Dosage Increases 30 Percent In Four Years

This article was originally published in PharmAsia News

Executive Summary

According to a recent report released by Japan's Ministry of Health, Labor and Welfare, the average daily dose of prescription sleeping pills per person in Japan increased 30 percent from 2005 to 2009

You may also be interested in...



Remdesivir India Sub-Licensing: Gilead Indicates Conditional Position For Subcontracting

Gilead clarifies position on Cipla’s sub-licensing effort for remdesivir, the investigational antiviral in the global spotlight as a potential treatment for COVID-19.

Coronavirus Update: Lilly Begins Clinical Trial Of Antibody Therapy

Discovered at record-breaking speed by AbCellera, Lilly says the antibody candidate could progress into Phase II trials by June.

EU Regulatory Roundup, May 2020: MDR Delay Sparks More Confusion, Uncertainty And Action

While the COVID-19 pandemic continued to dominate EU-wide medtech decisions in May, further analysis of the one-year delay to the EU’s new regulations revealed some unexpected consequences. Meanwhile, a new flurry of documents and decisions have been produced by the European Commission.

UsernamePublicRestriction

Register

ID1131161

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel